In this work, we have predominantly focused on the basic molecular mechanisms regulating RNA Pol II, but it has not escaped our notion that these discoveries open direct avenues to actionable synthetic (inactivation of the CDK12-gene in specific cancers) and combinatorial lethalities. The gene discussed is CDK12; the disease is cancer.